Click here to get full coverage on Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing  ts2.tech

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Trading 3% Higher - Still a Buy? - MarketBeat

Cytokinetics (NASDAQ:CYTK) Trading 3% Higher - Still a Buy?  MarketBeat

Cytokinetics (NASDAQ:CYTK) Trading 3% Higher - Still a Buy? - MarketBeat

Click here to get full coverage on Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? - Yahoo Finance

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)?  Yahoo Finance

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? - Yahoo Finance

Click here to get full coverage on Cytokinetics Stock Soars: What’s Next? - StocksToTrade

Cytokinetics Stock Soars: What’s Next?  StocksToTrade

Cytokinetics Stock Soars: What’s Next? - StocksToTrade

Click here to get full coverage on Cytokinetics: A Heavily Mispriced Cardiovascular Platform (NASDAQ:CYTK) - Seeking Alpha

Cytokinetics: A Heavily Mispriced Cardiovascular Platform (NASDAQ:CYTK)  Seeking Alpha

Cytokinetics: A Heavily Mispriced Cardiovascular Platform (NASDAQ:CYTK) - Seeking Alpha

Click here to get full coverage on Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Notice to Long-Term Shareholders of Cytokinetics, Inc.  GlobeNewswire

Notice to Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Click here to get full coverage on New heart drug MYQORZO approved to help adults with obstructive HCM symptoms - Stock Titan

New heart drug MYQORZO approved to help adults with obstructive HCM symptoms  Stock Titan

New heart drug MYQORZO approved to help adults with obstructive HCM symptoms - Stock Titan

Click here to get full coverage on New Analyst Forecast: $CYTK Given $95 Price Target - Quiver Quantitative

New Analyst Forecast: $CYTK Given $95 Price Target  Quiver Quantitative

New Analyst Forecast: $CYTK Given $95 Price Target - Quiver Quantitative

Click here to get full coverage on Goldman Sachs Upgrades Cytokinetics (CYTK) - Nasdaq

Goldman Sachs Upgrades Cytokinetics (CYTK)  Nasdaq

Goldman Sachs Upgrades Cytokinetics (CYTK) - Nasdaq

Click here to get full coverage on Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance

Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures  Yahoo Finance

Cytokinetics (CYTK) Valuation Check After Shareholder Investigation Into Aficamten FDA Review Disclosures - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes  ts2.tech

Cytokinetics (CYTK) Stock Hits 52-Week High as FDA Approval of Myqorzo Triggers Analyst Price-Target Hikes - ts2.tech

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock  MarketBeat

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 1,809 Shares of Stock - MarketBeat

Click here to get full coverage on Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha

Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK)  Seeking Alpha

Cytokinetics: Small Label Differences With Big Commercial Stakes (CYTK) - Seeking Alpha

Click here to get full coverage on Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - Nasdaq

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO  Nasdaq

Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - Nasdaq

Click here to get full coverage on Insider Sale: EVP of $CYTK Sells 1,042 Shares | CYTK Stock News - Quiver Quantitative

Insider Sale: EVP of $CYTK Sells 1,042 Shares | CYTK Stock News  Quiver Quantitative

Insider Sale: EVP of $CYTK Sells 1,042 Shares | CYTK Stock News - Quiver Quantitative

Click here to get full coverage on Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire

Notice to Long-Term Shareholders of Alexandria Real Estate  GlobeNewswire

Notice to Long-Term Shareholders of Alexandria Real Estate - GlobeNewswire

Click here to get full coverage on Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan

Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026  Stock Titan

Cytokinetics (Nasdaq: CYTK) gains positive CHMP view on MYQORZO oHCM therapy, EU ruling expected in Q1 2026 - Stock Titan

Click here to get full coverage on Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK) - Seeking Alpha

Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK)  Seeking Alpha

Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling (CYTK) - Seeking Alpha

Click here to get full coverage on Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ... - Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ...  Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Call Highlights: Progress Towards Aficamptin Approval ... - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance

Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative  Yahoo Finance

Cytokinetics (CYTK): Exploring Valuation After Recent Share Price Momentum and Growth Narrative - Yahoo Finance

Click here to get full coverage on Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits - Yahoo Finance

Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits  Yahoo Finance

Why CYTK Faces New Questions on Management Credibility Amid Regulatory Scrutiny and Investor Lawsuits - Yahoo Finance

Click here to get full coverage on The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga

The Year-End 2025 Biotech Rally And What It Means For 2026  Benzinga

The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga

Click here to get full coverage on Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - Yahoo Finance

Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising  Yahoo Finance

Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential?  Yahoo Finance

Cytokinetics (CYTK): Is the Current Market Valuation Overlooking the Company’s Long-Term Potential? - Yahoo Finance

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Click here to get full coverage on (CYTK) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(CYTK) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(CYTK) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - Yahoo Finance

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?  Yahoo Finance

Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed? - Yahoo Finance

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed?  Yahoo Finance

Cytokinetics (CYTK) Is Up 15.6% After Aficamten Outperforms Metoprolol in New Heart Data Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Noteworthy Monday Option Activity: RH, HIMS, CYTK - Nasdaq

Noteworthy Monday Option Activity: RH, HIMS, CYTK  Nasdaq

Noteworthy Monday Option Activity: RH, HIMS, CYTK - Nasdaq

Click here to get full coverage on Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK)  GuruFocus

Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus

Click here to get full coverage on Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit  PR Newswire

Do you own shares of CYTK? Robbins LLP Informs Investors of the Cytokinetics, Inc. Class Action Lawsuit - PR Newswire

Click here to get full coverage on Cytokinetics (CYTK) director Kaye sells $1.87 million in stock - Investing.com

Cytokinetics (CYTK) director Kaye sells $1.87 million in stock  Investing.com

Cytokinetics (CYTK) director Kaye sells $1.87 million in stock - Investing.com

Click here to get full coverage on Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Attention Long-Term Shareholders of Cytokinetics, Inc.  GlobeNewswire

Attention Long-Term Shareholders of Cytokinetics, Inc. - GlobeNewswire

Click here to get full coverage on Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK  MarketBeat

Squarepoint Ops LLC Has $608,000 Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Zacks Investment Research

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?  Zacks Investment Research

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Zacks Investment Research

Click here to get full coverage on Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock  MarketBeat

Andrew Callos Sells 1,042 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Click here to get full coverage on B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation  Nasdaq

B. Riley Securities Reiterates Cytokinetics (CYTK) Buy Recommendation - Nasdaq

Click here to get full coverage on First Week of August 2026 Options Trading For Cytokinetics (CYTK) - Nasdaq

First Week of August 2026 Options Trading For Cytokinetics (CYTK)  Nasdaq

First Week of August 2026 Options Trading For Cytokinetics (CYTK) - Nasdaq

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat

Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock  MarketBeat

Cytokinetics (NASDAQ:CYTK) Director Sells $1,322,800.00 in Stock - MarketBeat

Click here to get full coverage on Cytokinetics (CYTK): Evaluating Valuation After FDA Approval of First oHCM Therapy MYQORZO - simplywall.st

Cytokinetics (CYTK): Evaluating Valuation After FDA Approval of First oHCM Therapy MYQORZO  simplywall.st

Cytokinetics (CYTK): Evaluating Valuation After FDA Approval of First oHCM Therapy MYQORZO - simplywall.st

Click here to get full coverage on Insider Sale: Director at $CYTK Sells 4,375 Shares - Quiver Quantitative

Insider Sale: Director at $CYTK Sells 4,375 Shares  Quiver Quantitative

Insider Sale: Director at $CYTK Sells 4,375 Shares - Quiver Quantitative

Click here to get full coverage on Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat

Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK)  MarketBeat

Investors Buy Large Volume of Cytokinetics Call Options (NASDAQ:CYTK) - MarketBeat

Click here to get full coverage on Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan  Yahoo Finance

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - Yahoo Finance

Click here to get full coverage on Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK)  Seeking Alpha

Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha

Click here to get full coverage on Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat

Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price  MarketBeat

Citizens Jmp Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - MarketBeat

Click here to get full coverage on Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Cytokinetics Inc (CYTK) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Yahoo Finance

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?  Yahoo Finance

Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug? - Yahoo Finance

Click here to get full coverage on Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating - TipRanks

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating  TipRanks

Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating - TipRanks

Click here to get full coverage on Cytokinetics (CYTK) director Kaye sells $336,789 in stock - Investing.com

Cytokinetics (CYTK) director Kaye sells $336,789 in stock  Investing.com

Cytokinetics (CYTK) director Kaye sells $336,789 in stock - Investing.com

Click here to get full coverage on Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Herald and News

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ...  Herald and News

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. ... - Herald and News

Click here to get full coverage on Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline - Nasdaq

Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline  Nasdaq

Earnings Preview: Cytokinetics (CYTK) Q3 Earnings Expected to Decline - Nasdaq

Click here to get full coverage on Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Brokerages  MarketBeat

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Click here to get full coverage on Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK - Morningstar

Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK  Morningstar

Investors who lost money on Cytokinetics, Incorporated(CYTK) should contact Levi & Korsinsky about pending Class Action - CYTK - Morningstar

Click here to get full coverage on RBC Capital Raises Price Target for Cytokinetics (CYTK) to $95 | - GuruFocus

RBC Capital Raises Price Target for Cytokinetics (CYTK) to $95 |  GuruFocus

RBC Capital Raises Price Target for Cytokinetics (CYTK) to $95 | - GuruFocus

Click here to get full coverage on Insider Sale: President & CEO of $CYTK Sells 5,000 Shares | CYTK Stock News - Quiver Quantitative

Insider Sale: President & CEO of $CYTK Sells 5,000 Shares | CYTK Stock News  Quiver Quantitative

Insider Sale: President & CEO of $CYTK Sells 5,000 Shares | CYTK Stock News - Quiver Quantitative

Click here to get full coverage on Cytokinetics (CYTK) Sees Upgraded Price Target by Barclays | CYT - GuruFocus

Cytokinetics (CYTK) Sees Upgraded Price Target by Barclays | CYT  GuruFocus

Cytokinetics (CYTK) Sees Upgraded Price Target by Barclays | CYT - GuruFocus

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire

Click here to get full coverage on $CYTK stock is up 37% today. Here's what we see in our data. - Quiver Quantitative

$CYTK stock is up 37% today. Here's what we see in our data.  Quiver Quantitative

$CYTK stock is up 37% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat

Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK  MarketBeat

Sanders Morris Harris LLC Takes $1.18 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat

Click here to get full coverage on Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Yahoo Finance

Why Cytokinetics, Inc. (CYTK) Went Down On Friday  Yahoo Finance

Why Cytokinetics, Inc. (CYTK) Went Down On Friday - Yahoo Finance

Click here to get full coverage on Cytokinetics (NASDAQ:CYTK) Price Target Raised to $84.00 at Needham & Company LLC - MarketBeat

Cytokinetics (NASDAQ:CYTK) Price Target Raised to $84.00 at Needham & Company LLC  MarketBeat

Cytokinetics (NASDAQ:CYTK) Price Target Raised to $84.00 at Needham & Company LLC - MarketBeat

Click here to get full coverage on Cytokinetics (CYTK) CEO Blum sells $300k in shares - Investing.com

Cytokinetics (CYTK) CEO Blum sells $300k in shares  Investing.com

Cytokinetics (CYTK) CEO Blum sells $300k in shares - Investing.com

Click here to get full coverage on How First FDA Approval For MYQORZO In oHCM At Cytokinetics (CYTK) Has Changed Its Investment Story - simplywall.st

How First FDA Approval For MYQORZO In oHCM At Cytokinetics (CYTK) Has Changed Its Investment Story  simplywall.st

How First FDA Approval For MYQORZO In oHCM At Cytokinetics (CYTK) Has Changed Its Investment Story - simplywall.st

Click here to get full coverage on Harrington sells Cytokinetics (CYTK) stock worth $143,620 - Investing.com

Harrington sells Cytokinetics (CYTK) stock worth $143,620  Investing.com

Harrington sells Cytokinetics (CYTK) stock worth $143,620 - Investing.com

Click here to get full coverage on Cytokinetics (CYTK) Gains FDA Approval for Myqorzo - GuruFocus

Cytokinetics (CYTK) Gains FDA Approval for Myqorzo  GuruFocus

CYTK

Price Chart

Key Statistics

Technicals

About CYTK

Latest News

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing - ts2.tech

Cytokinetics (NASDAQ:CYTK) Trading 3% Higher - Still a Buy? - MarketBeat

Is First U.S. MYQORZO Approval Reshaping The Investment Case For Cytokinetics (CYTK)? - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers